Want to see IN:DIVISLAB full AI Analyst Report?
DIVISLAB Stock Chart & Stats
₹8680.00
₹165.50(2.28%)
At close: 4:00 PM EDT
₹8680.00
₹165.50(2.28%)
Day’s Range― - ―
52-Week Range₹5,648.00 - ₹10,000.00
Previous CloseN/A
Volume544.67K
Average Volume (3M)33.51K
Market Cap
₹2.41T
Enterprise Value₹1.54T
Total Cash (Recent Filing)₹32.33B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)82.4
Beta0.78
Next Earnings
Nov 09, 2026EPS Estimate
32.1Next Dividend Ex-DateN/A
Dividend Yield0.33%
Share Statistics
EPS (TTM)110.22
Shares Outstanding265,468,570
10 Day Avg. Volume50,182
30 Day Avg. Volume33,510
Financial Highlights & Ratios
PEG Ratio3.57
Price to Book (P/B)9.42
Price to Sales (P/S)14.95
P/FCF Ratio317.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹9,100.00Price Target Upside4.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)125.04
Revenue Forecast (FY)₹126.12B
Bulls Say, Bears Say
Bulls Say
Fortress Balance SheetExceptionally low leverage gives Divi’s Laboratories substantial resilience across industry cycles and preserves flexibility to fund expansion, absorb operational volatility, or return capital. Continued equity growth also indicates that the business is compounding its capital base without relying heavily on debt.
Revenue And Earnings RecoveryThe rebound in revenue and absolute earnings demonstrates renewed operating momentum after the softer 2025 period. Higher scale and growing profits can strengthen internal funding capacity, support investment in pharmaceutical capabilities, and reinforce the company’s position with global API and contract-manufacturing customers.
Improving Operating Cash FlowStrongly improving operating cash flow indicates that reported profitability is increasingly being converted into cash from the core business. This supports ongoing capital investment, improves financial self-sufficiency, and gives Divi’s greater capacity to manage customer, product-cycle, and regulatory demands over the coming quarters.
Bears Say
Uneven Free Cash FlowFree cash flow remains materially less consistent than operating cash flow, suggesting that reinvestment, capital spending, or working-capital movements can absorb a significant share of internally generated funds. This variability may constrain the timing of expansion and reduce predictability of excess cash available to stakeholders.
Margin NormalizationAlthough profitability remains strong for the industry, the decline from the 2022 net-margin peak indicates that earlier earnings economics have not been fully sustained. Continued normalization could limit earnings growth relative to revenue growth and leave future results more dependent on product mix, pricing, and manufacturing efficiency.
Slower Recent Revenue GrowthThe recovery in revenue is encouraging, but the recent growth pace remains moderate and followed a near-flat 2025. If this slower trajectory persists, operating leverage and earnings expansion may become less powerful, placing greater importance on new molecule demand, customer schedules, and execution in APIs and custom synthesis.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹5648.00 and its highest was ₹10000.00 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹2.41T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on Aug 01, 2026. The company reported ₹33.95 earnings per share for the quarter, beating the consensus estimate of ₹25.392 by ₹8.558.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Undervalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.33%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 32.1.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹33.95 in its last earnings report, beating expectations of ₹25.392. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
DIVISLAB Stock 12 Month Forecast
Average Price Target
₹9,100.00
▲(4.84% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Granules India Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―








